New, Expanded Laboratory and Manufacturing Capabilities

New, Expanded Laboratory and Manufacturing Capabilities
Part of Aushon's Corporate Headquarters Renovation

 State-of-the-art facility offers increased capacity and enhanced process automation to meet the growing demand for Aushon's multiplex immunoassay products and services

Billerica, Mass.,Sep 9, 2009 - Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that it has completed the renovation and expansion of its Billerica, MA corporate headquarters. A key component of the project included the design and construction of new laboratory and manufacturing areas, which will increase capacity while improving quality and performance. As a result of the renovations, Aushon was also able to relocate the recently acquired SearchLight business and laboratory operations from Woburn, MA, to its new facility. 

"We're experiencing strong demand for our multiplex solutions, especially in the clinical trials segment," said Joe Blanchard, COO of Aushon.  "As a result, the renovations included an expansion doubling our capacity for multiplex immunoassay product manufacturing, as well as our testing and development services. This major investment underscores our continued commitment to the protein biomarker business."

Increased Automation for Improved Performance
The expanded laboratory and manufacturing center features increased levels of automation designed to optimize performance by improving throughput and limiting variability in production processes. In addition, the CLIA-certified laboratories include a BL-2 level lab, plus clean and cold rooms.

"At this stage of our company's development, consolidating our business under one roof makes sense," said Peter Honkanen, CEO of Aushon. "It allows us to work more efficiently, encourages collaboration and innovation, and takes advantage of the inherent synergies that inspired Aushon to acquire the SearchLight business and technology assets."

Aushon SearchLight products and services include:

Protein Biomarker Sample Testing Service: A convenient, custom service that allows researchers to submit samples for quantitative analysis in custom SearchLight Biomarker Arrays
Custom Arrays and Assay Development: Select from a menu of more than 300 proteins to design an array consisting of 2 to 16 proteins per well.
Chemiluminescent and Infrared Assay Kits: Choose from a list of in-stock angiogenesis, cytokine, chemokine and MMP arrays; each is supplied with a complete set of detection antibody cocktails and detection reagents.  
Aushon 2470 Arrayer: The industry's most reliable microarray printer provides researchers with a single instrument for genomic and proteomic microarray applications, with unmatched sample and substrate flexibility and unequaled accuracy.
Custom Microarray Printing: Unmatched versatility and flexibility means printing virtually any sample on any substrate - with unequaled reproducibility, accuracy and rapid turnaround.
About Aushon BioSystems
Aushon BioSystems provides a comprehensive suite of microarray instruments, consumables and services to leading pharmaceutical, biotechnology, academic and diagnostic clients worldwide. Our unique combination of advanced microarray printing technology, robust biomarker content and innovative multiplex immunoassay development and detection systems delivers exceptional performance, quality and reliability that accelerate pre-clinical and clinical biomarker research. Our customers trust us to provide the most reliable protein biomarker data available, which lowers costs and improves research productivity. For more information, please visit www.aushon.com.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.